| Dian Kang |
Dian Kang is a Chinese businessperson who has been at the helm of 7 different companies is on the board of China Vanke Co., Ltd., Hongkong Swiss Investment Management Co. Ltd., Shenzhen Pansum Technology Co., Ltd. and Genetron Holdings Ltd. In his past career he was Chairman & Chief Executive Officer for New China Life Insurance Co., Ltd. and Chairman of New China Asset Management Co., Ltd. (a subsidiary of New China Life Insurance Co., Ltd.), Chairman for Springridge Investment Management Ltd., Chairman & General Manager of Guangdong Capital Holdings Ltd., Chairman for Guangdong Asia Insurance Co. Ltd., Vice President of China Agribusiness Trust & Investment Corp., Chairman-Supervisory Board for Shenzhen Development Bank Co. Ltd., Chairman of Sinolink Securities (Hong Kong) Co. Ltd., Director-Overseas Project Management at CITIC Group Corp., Vice President at China National Packaging Corp. and Director & Vice President at Guangdong Enterprises (Holdings) Ltd.
He received a graduate degree from Chinese Academy of Social Sciences and an undergraduate degree from the University of Science & Technology Beijing. |
| Wing Kee Lau |
Wing Kee Lau holds the position of Chief Financial Officer & Co-Secretary at RoboSense Technology Co., Ltd. He is also on the board of EHang Holdings Ltd. and Genetron Holdings Ltd. and Member of Hong Kong Institute of Certified Public Accountants and Member of Association of Chartered Certified Accountants.
In his past career Mr. Lau occupied the position of Chief Financial Officer & Secretary for Beijing Media Corp. Ltd., Chief Financial Officer for Tarena International, Inc., Chief Financial Officer of Learning Squared, Inc., Chief Financial Officer & Director at Perfect World Co., Ltd., Group Director-Finance at Shanghai Ogilvy & Mather Advertising Ltd. and Audit Senior Manager at PricewaterhouseCoopers (Beijing).
Mr. Lau received an undergraduate degree from Hong Kong Baptist University and an MBA from Cheung Kong Graduate School of Business. |
| Shan Fu |
Shan Fu joined Vivo in 2013 as a Managing Partner, Co-CEO and CEO of Greater China. Before joining Vivo, Mr. Fu worked for Blackstone as Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office. Mr. Fu also worked in the Department of Foreign Investment in China’s National Development and Reform Commission (NDRC), the State Economic and Trade Commission of China, the Office of Economic and Trade in State Council of China, and the Office of Production in State Council of China.
Mr. Fu received a Bachelor’s and Master’s Degree in History from Peking University in Beijing, China. |
| Hai Yan |
Hai Yan founded Genetron Holdings Ltd. and Beijing Genetron Biotechnology Co. Ltd. He is Director & Chief Scientific Officer at Genetron Holdings Ltd. and Chief Science Officer at Beijing Genetron Biotechnology Co. Ltd. (a subsidiary of Genetron Holdings Ltd.). He is also on the board of Beijing Genetron Health Gene Technology Co. Ltd. and Member of American Society for Clinical Investigation and Co-Director-Neuro Oncology Program at Duke Cancer Institute.
In the past Mr. Yan held the position of Associate at The Johns Hopkins University.
He received a doctorate from Peking University Health Science Center and a doctorate from The Trustees of Columbia University in The City of New York. |
| Si Zhen Wang |
Founder of Genetron Holdings Ltd. and Beijing Genetron Biotechnology Co. Ltd., Si Zhen Wang presently is Chairman & Chief Executive Officer of Genetron Holdings Ltd. and Chief Executive Officer for Beijing Genetron Biotechnology Co. Ltd. and General Manager & Director at Beijing Genetron Health Gene Technology Co. Ltd. (both are subsidiaries of Genetron Holdings Ltd.).
He received an undergraduate degree from Central University of Finance & Economics and an MBA from École des Hautes Études Commerciales de Paris. |
| Webster Cavenee |
Webster Cavenee is on the board of Genetron Holdings Ltd.
In the past he was Director-Strategic Alliances at Ludwig Cancer Research and Member of Ludwig Cancer Research.
He received an undergraduate degree from Kansas State University and a doctorate from the University of Kansas. |
| Yu Chen Jiao |
Presently, Yu Chen Jiao is Chief Technology Officer for Genetron Holdings Ltd. He is also on the board of Beijing Genetron Health Gene Technology Co. Ltd. and Professor at Chinese Academy of Medical Sciences.
He received a doctorate from Peking Union Medical College and a doctorate from The Johns Hopkins University. |
| Ce Xu |
Currently, Ce Xu holds the position of Chief Financial Officer for Genetron Holdings Ltd.
Ce Xu received an undergraduate degree and a graduate degree from National University of Singapore. |
| Ying Hong |
Ying Hong is Chief Operating Officer of Genetron Holdings Ltd. |
| Xia Wu |
Xia Wu is on the board of Genetron Holdings Ltd., Shanghai MicroPort CardioFlow Medtech Co., Ltd., MicroPort CardioFlow Medtech Corp. and MicroPort NeuroTech Ltd. She previously held the position of Executive Director at CICC Jiacheng Investment Management Co. Ltd.
Ms. Wu received an undergraduate degree from Peking University and a graduate degree from Warwick Business School. |
| Chao Tang |
Chao Tang is on the board of Genetron Holdings Ltd. and Executive Dean at Peking University.
Dr. Tang previously occupied the position of Professor at The University of California, San Francisco.
He received an undergraduate degree from the University of Science & Technology of China and a doctorate from The University of Chicago. |
| Yun Fu Hu |
Yun Fu Hu is Chief Medical Officer at Genetron Holdings Ltd.
In the past Dr. Hu occupied the position of Associate Director at Vitro Biopharma, Inc. and Deputy Director at US Food & Drug Administration.
He received an undergraduate degree from Huazhong Agricultural University and a graduate degree and a doctorate from The Ohio State University. |
